Navigation Links
Study Shows ResMed's New CPAP Device Increases Patient Compliance
Date:9/16/2010

SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- ResMed (NYSE: RMD), a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment today announced the results of a clinical study confirming that patients' compliance with sleep therapy increases when using ResMed's new CPAP device.

(Logo:  http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100203/RESMEDLOGO)

The clinical study of 50 patients suffering from sleep apnoea showed an improvement of 30 minutes in average daily usage, from a mean of 6 hours 35 minutes on the patient's usual CPAP device, to 7 hours 5 minutes, when using the new S9 Series.

Sleep apnoea is one of the more common, and yet highly undiagnosed, sleep disorders. Obstructive sleep apnoea (OSA) is the most common type of sleep apnoea and is marked by the collapse or obstruction of the airway during sleep. The most effective treatment is Continuous Positive Airway Pressure (CPAP) therapy. In this non-invasive treatment, air is pressurised by a small device and delivered to the airway of the patient through a mask that fits on/over the nose, or nose and mouth. The pressurised air keeps the upper airway open and helps the person to get a restful night without interruptions caused by apnoeas.

A patient's ability to comply with sleep therapy, however, is affected by potential negative side effects, such as noise from the device, nasal dryness/congestion and breathing discomfort. To combat these side effects and increase patients' ability to adhere to the sleep therapy, ResMed has developed new improved features for its S9 Series including reduced noise, improved humidification system, and a more comfortable breathing system.

After testing ResMed's new sleep apnoea therapy platform, patients rate the S9 Series as significantly better than their current device in comfort of breathing, dryness of nose and mouth, rainout, and noise. In terms of overall preference, 78% preferred the S9 Series, over their current device.

"For the first time with our new ClimateControl™ system, air is delivered quietly and comfortably at the precise temperature and humidity that the sleeping patient, provider, and physician have set.  S9 Series provides a significant, patient-perceptible difference in comfort; a true leap-forward for sleep apnoea therapy," said Michael Farrell, SVP of the Global Sleep Business Unit at ResMed.

Studies conducted by researchers at Harvard Medical School show that a lack of sleep negatively affects perception and judgment. In the workplace sleep deprivation can result in reduced efficiency and productivity, errors, and accidents. Studies from the Clinical Sciences Research Institute at the University of Warwick suggest that between 6-8 hours of sleep is the optimal range.

"We are extremely pleased to see patient tests confirm that the S9 Series increases patient's compliance and quality of life, making the device a true revolution in positive airway pressure therapy," added Frank Klein, VP, European Sleep Business Unit at ResMed.

About the study

The ResMed S9 Compliance Study was conducted as a clinical study of 50 patients at the ResMed Sleep Research Centre in Sydney, Australia. The three month study comprised three stages: a retrospective study where the patients used their own device for 28 days, followed by 28 days testing S9 in a prospective study, and finally returning to the patient's own device for 28 more days in a prospective study.  

The purpose of the study was to assess whether compliance is improved by ResMed's new S9 Series, which features reduced noise, an improved humidification system and a more comfortable breathing experience. In terms of average daily usage, compliance on the S9 Series was significantly better than compliance on the patient's own device, both before and after trialling an S9 device.

The study is registered in the clinical trial registry ClinicalTrials.gov, Identifier: NCT01013207

About the S9 Series

The S9 Series is designed to deliver unsurpassed comfort to the patient by automatically controlling the pressure, temperature and humidity of the air that the patient breathes. The temperature as well as the humidity is controlled through input from five different sensors, including sensors close to the mask, a feature unique to the S9 Series over any of its competition. Optimal humidification is then achieved automatically. A new enhanced Easy-Breathe motor also reduces the conducted noise offering the quietest mask and machine combination available on the market.

About ResMed

ResMed is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contact ResMed:

Further information can be obtained by contacting Constance Bienfait at ResMed Inc., San Diego, at (858) 836-5971; Brett Sandercock at ResMed Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's multilingual Web site at www.resmed.com.  


'/>"/>
SOURCE ResMed
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... December 9, 2016 External ... Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization Therapy Defibrillators ... Cardioverter Defibrillators The global defibrillators ... CAGR of 5.3% from 2016-2020 and CAGR of ... grow at a CAGR of 5.2% from 2016 ...
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... the global optical transceiver market to grow at a CAGR of ... the present scenario and the growth prospects of the global optical ... considers the revenue generated from the shipment of optical transceivers worldwide ...
(Date:12/9/2016)... 9, 2016 Mitsubishi Tanabe Pharma Corporation (Head ... Director, CEO: Dr. Masayuki Mitsuka ) has presented ... given edaravone intravenously in 10-14 day cycles for 48 ... the ALS Functional Rating Scale-Revised (ALSFRS-R). The data were ... ALS/MND in Dublin, Ireland . ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... MEDI+SIGN®, a provider of fully-automated patient monitoring ... for Emergency Departments (ED) has been added to their portfolio. Housed in a ... and with a simplified pallet of information available to the patient, the Digital ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... , ... December 08, 2016 , ... David J. ... global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, ... the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology ...
Breaking Medicine News(10 mins):